Evidence map›Paper›PMID 24550192›Full record

ArticleDiabetes2014

Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility.

Henna Kallionpää, Laura L Elo, Essi Laajala, Juha Mykkänen, Isis Ricaño-Ponce, Matti Vaarma, Teemu D Laajala, Heikki Hyöty, Jorma Ilonen, Riitta Veijola and 6 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 1 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. IFN-α Neutralizing Antibodies Distinguish LADA From Early-onset Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 2 countries.

Henna KallionpääTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, FinlandTurku Doctoral Programme of Biomedical Sciences, Turku, FinlandThe Finnish Centre of Excellence in Molecular Systems Immunology and Physiology Research, Helsinki, Finland.
Laura L EloTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, FinlandBiomathematics Research Group, Department of Mathematics, University of Turku, Turku, Finland.
Essi LaajalaTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, FinlandThe Finnish Centre of Excellence in Molecular Systems Immunology and Physiology Research, Helsinki, FinlandDepartment of Information and Computer Science, Aalto University School of Science, Aalto, FinlandThe National Graduate School in Informational and Structural Biology, Turku, Finland.
Juha MykkänenTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, FinlandThe Finnish Centre of Excellence in Molecular Systems Immunology and Physiology Research, Helsinki, FinlandDepartment of Pediatrics, University of Turku, Turku, FinlandDepartment of Pediatrics, Turku University Hospital, Turku, Finland.
Isis Ricaño-PonceDepartment of Genetics, University of Groningen, University Medical Centre, Groningen, the Netherlands.
Matti VaarmaDepartment of Signal Processing, Tampere University of Technology, Tampere, Finland.
Teemu D LaajalaTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Heikki HyötyDepartment of Virology, University of Tampere, Tampere, FinlandFimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland.
Jorma IlonenImmunogenetics Laboratory, University of Turku, Turku, FinlandDepartment of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland.
Riitta VeijolaDepartment of Pediatrics, University of Oulu and Oulu University Hospital, Oulu, Finland.
Tuula SimellThe Finnish Centre of Excellence in Molecular Systems Immunology and Physiology Research, Helsinki, FinlandDepartment of Pediatrics, University of Turku, Turku, Finland.
Cisca WijmengaDepartment of Genetics, University of Groningen, University Medical Centre, Groningen, the Netherlands.
Mikael KnipThe Finnish Centre of Excellence in Molecular Systems Immunology and Physiology Research, Helsinki, FinlandChildren's Hospital, University of Helsinki and Helsinki University Central Hospital, Helsinki, FinlandFolkhälsan Research Center, Helsinki, FinlandDepartment of Pediatrics, Tampere University Hospital, Tampere, Finland.
Harri LähdesmäkiTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, FinlandThe Finnish Centre of Excellence in Molecular Systems Immunology and Physiology Research, Helsinki, FinlandDepartment of Information and Computer Science, Aalto University School of Science, Aalto, Finland.
Olli SimellThe Finnish Centre of Excellence in Molecular Systems Immunology and Physiology Research, Helsinki, FinlandDepartment of Pediatrics, University of Turku, Turku, FinlandDepartment of Pediatrics, Turku University Hospital, Turku, Finland.
Riitta LahesmaaTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, FinlandThe Finnish Centre of Excellence in Molecular Systems Immunology and Physiology Research, Helsinki, Finland riitta.lahesmaa@btk.fi.
Turku Centre for Biotechnology · FIUniversity of Turku · FIInstitute for Molecular Medicine Finland · FIUniversity Medical Center Groningen · NLÅbo Akademi University · FIPirkanmaa Hospital District · FITampere University · FITampere University Hospital · FIUniversity of Oulu · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The insult leading to autoantibody development in children who will progress to develop type 1 diabetes (T1D) has remained elusive. To investigate the genes and molecular pathways in the pathogenesis of this disease, we performed genome-wide transcriptomics analysis on a unique series of prospective whole-blood RNA samples from at-risk children collected in the Finnish Type 1 Diabetes Prediction and Prevention study. We studied 28 autoantibody-positive children, out of which 22 progressed to clinical disease. Collectively, the samples covered the time span from before the development of autoantibodies (seroconversion) through the diagnosis of diabetes. Healthy control subjects matched for date and place of birth, sex, and HLA-DQB1 susceptibility were selected for each case. Additionally, we genotyped the study subjects with Immunochip to identify potential genetic variants associated with the observed transcriptional signatures. Genes and pathways related to innate immunity functions, such as the type 1 interferon (IFN) response, were active, and IFN response factors were identified as central mediators of the IFN-related transcriptional changes. Importantly, this signature was detected already before the T1D-associated autoantibodies were detected. Together, these data provide a unique resource for new hypotheses explaining T1D biology.

Indexed as

Immunity, InnateAdolescentAutoantibodiesCase-Control StudiesChildChild, PreschoolDiabetes Mellitus, Type 1FemaleGenetic Predisposition to DiseaseGenotypeHLA-DQ beta-ChainsHumansMaleMicroarray AnalysisTranscriptomeAutoantibodiesHLA-DQB1 antigenHLA-DQ beta-Chains

Identifiers

PMID24550192
OpenAlexW2099224853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.